European Journal of Medicinal Chemistry p. 455 - 464 (2019)
Update date:2022-07-29
Topics:
Winters, Maria
DuHadaway, James B.
Pham, Khoa N.
Lewis-Ballester, Ariel
Badir, Shorouk
Wai, Jenny
Sheikh, Eesha
Yeh, Syun-Ru
Prendergast, George C.
Muller, Alexander J.
Malachowski, William P.
Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2.
View MoreLinHai Cina Chemical Co., LTD.
Contact:0576-85580989
Address:Pharma-chem zone,Duqiao,Linhai,Zhejiang,China
Contact:86-532-68629711 13780605697
Address:NO 220 YANAN 3 ROAD,(POST ADMINISTRATION BUILDING),QINGDAO,CHINA
Contact:886 2 2541 0022
Address:8 Fl., No. 11, Sec. 1, Chung Shan North Rd., Taipei, Taiwan R.O.C.
Tianjin Anda North Industrial & Business Co.Ltd.
Contact:86-22-24999306
Address:No.11 Erwei Road,Dongli Development Area,Tianjin,China
Jinan Trio PharmaTech Co., Ltd
Contact:86-531-88811783;+(0)13153010282
Address:2766 Yingxiu Road, Jinan High-Tech Zone, China
Doi:10.1021/ol900779v
(2009)Doi:10.1016/0008-6215(87)85004-8
(1987)Doi:10.1016/j.jorganchem.2008.09.059
(2009)Doi:10.1002/jhet.5570390104
(1898)Doi:10.1021/acs.orglett.9b01192
(2019)Doi:10.1016/S0040-4039(00)96366-4
(1987)